Welcome to our dedicated page for MediciNova news (Ticker: $MNOV), a resource for investors and traders seeking the latest updates and insights on MediciNova stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MediciNova's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MediciNova's position in the market.
MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering MN-166 (ibudilast) for treating chlorine-induced acute respiratory distress syndrome (ARDS). This patent, expected to expire no earlier than January 2042, includes claims for MN-166 as a monotherapy or in combination with other drugs, and covers various administration methods and dosing frequencies. The announcement follows a promising nonclinical model study showing significant improvements in pulmonary function and survival rates with MN-166. Chief Medical Officer Kazuko Matsuda expressed optimism about the potential value this patent adds to MN-166.
MediciNova, Inc. has received a new patent from the U.S. Patent and Trademark Office covering extended-release formulations of MN-166 (ibudilast), set to expire after September 2040. The patent includes claims for tablet or capsule formulations at various doses. Chief Medical Officer, Kazuko Matsuda, sees this patent as enhancing the value of MN-166 by offering patient convenience and potentially reducing side effects.